Company intelligence / Profile preview
Algiax Pharmaceuticals
Erkrath, Nordrhein-Westfalen, Germanyalgiax.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Algiax recently completed a Phase 2a clinical trial for AP-325 in chronic neuropathic pain with positive results. The study demonstrated rapid onset of action with clinically meaningful pain reduction within two weeks, persistent treatment effects suggesting disease modification, high responder rates (over 25% of patients showing ≥50% pain reduction vs 11% for placebo), reduced need for rescue medication, favorable Number Needed to Treat compared to standard of care, improved sleep quality, reduced anxiety and depression, and a good safety profile with side effects comparable to placebo and no central side effects.[9][10]
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Algiax Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Algiax Pharmaceuticals.